— On Cora’s radar

Peptides, done right.

Beyond weight loss. If provider-guided peptide therapy ever becomes available, it would be held to the same standard as every Cora plan — licensed providers, a US-licensed 503A pharmacy. Not yet available and not FDA-approved. Leave your email and you’re first in line if it opens.

First access, one launch email. Unsubscribe anytime.

Compounded therapies are not FDA-approved and are not yet available.

Illustrative vials — compounded peptide therapies in development, not yet available — Concept render — if offered, prepared by a US-licensed 503A pharmacy, not by Cora. In development

— What peptides are

Short chains, big questions.

Peptides are short chains of amino acids — the same class of molecule as the compounded GLP-1 medications that licensed providers prescribe through Cora. Different peptides are being studied for a range of goals beyond weight loss, from tissue repair to inflammation.

That research is early. For several of the peptides in the news right now, the human evidence is thin — a single small study, or none at all. None of them is FDA-approved, none is offered through Cora today, and nothing on this page is a medical claim.

— Where this actually stands

Recommended is not approved.

Over July 23-24, 2026, an FDA advisory committee reviewed seven peptides and voted to recommend six of them — including BPC-157 — for the list of substances pharmacies may compound under Section 503A, while rejecting one (Emideltide, also called DSIP). It is worth being precise about what that did, and did not, do.

A recommendation from that committee is non-binding, and in this case it went against the FDA’s own staff scientists. It is not FDA approval, and it does not make any peptide legal to compound today — that would require a separate FDA rulemaking that has not happened, a process that has historically taken 12 to 24 months and that the FDA can still decline. We are not putting a date on it, and you should be wary of anyone who does.

So the honest status today: these peptides are not FDA-approved, and they are not offered through Cora. When the picture changes, we will say so plainly — here first.

Read the full explainer See the Peptide Compounding Status Index

Status, sources and evaluated uses for each one: BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax, Epitalon.

— Built on the same standard

New category. Same promise.

Same providers
Licensed providers, every plan.

Nothing ships without a board-certified provider reviewing your history and deciding it’s right for you.
Same pharmacy standard
A US-licensed 503A pharmacy.

If a therapy is offered, it’s compounded by a US-licensed 503A pharmacy — the same standard behind every Cora plan.
Same honest pricing
Every price up front.

If peptide therapy ever becomes available (it is not yet available and is not FDA-approved), every price and commitment length would be shown up front before you pay — total cost, no hidden fees.

— How legitimate access would work

If it opens, it opens the right way.

If — and only if — a compliant, legal pathway for a given peptide opens, here is how access would work at Cora. Every step below is conditional and describes something that is not yet available and is not FDA-approved.

1 A licensed provider reviews your history and decides whether a therapy is appropriate for you — nothing is dispensed without that review.
2 A named, US-licensed 503A pharmacy — Hallandale Pharmacy (PCAB-accredited) or VialsRx — compounds it under a patient-specific prescription. Cora never compounds or prescribes directly.
3 Every price and commitment length is shown up front, before you pay — the transparent alternative to the grey-market sellers who promise more than the science supports.

Join the list

From waitlist to doorstep.

TODAY

Join the list

Add your email. No commitment, no card — just first access when it opens.

AT LAUNCH

A provider reviews you

Tell us your goals; a licensed provider decides what, if anything, is appropriate.

3–5 DAYS

Delivered to your door

Compounded by a US-licensed 503A pharmacy and shipped discreetly, with provider support.

— Common questions

Everything you wondered, answered.

What exactly are peptides?

Peptides are short chains of amino acids — the same class of molecule as the compounded GLP-1 medications that licensed providers prescribe through Cora. Different peptides are being explored for a range of goals beyond weight loss. The therapies referenced here are not yet available and are not FDA-approved.

Are these FDA-approved?

No. Compounded peptide therapies are not FDA-approved and are not therapeutically equivalent to any FDA-approved product. Nothing on this page is a medical claim or a substitute for medical advice. If and when peptide therapy is available through Cora, a licensed provider will determine whether it’s appropriate for you.

When does this launch?

It’s in development now. People on the waitlist get first access — and an honest heads-up the moment it’s live. No spam in the meantime.

Will it be the same providers and pharmacy?

Yes. Any peptide therapy would run on the same foundation as Cora’s weight-loss plans: licensed providers write the prescriptions, and a US-licensed 503A pharmacy prepares the medication. Cora never compounds or prescribes directly.

— Get first access

Be first in line, today.

Drop your email and you’ll know the moment peptides go live — before anyone else. No commitment, no card, no spam.

By joining you agree to hear from Cora about the peptides launch. Unsubscribe anytime.

Compounded therapies are not FDA-approved and are not yet available.

Peptide therapies and product imagery on this page are illustrative, not yet available, and not FDA-approved. They are not therapeutically equivalent to any FDA-approved product, and nothing here is a medical claim or a substitute for professional medical advice. If offered, therapies would be prescribed only by a licensed provider when appropriate and compounded by a US-licensed 503A pharmacy. Individual results vary.